Novo Cuts Outlook, Pledges Crackdown On Copycat Obesity Drugs

zerohedge.com/markets/novo-cuts-outlook-copycat-anti-obesity-drugs-hit-sales

Novo Cuts Outlook, Pledges Crackdown On Copycat Obesity Drugs

Novo Nordisk shares surged as much as 6.5% in European trading, making it a top performer on the Stoxx 600, as Wall Street analysts said the Danish drugmaker's guidance cut was largely priced in—and pressures on Wegovy sales…

This story appeared on zerohedge.com, 2025-05-07 11:45:00.
The Entire Business World on a Single Page. Free to Use →